<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23180">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01651013</url>
  </required_header>
  <id_info>
    <org_study_id>CALLAS</org_study_id>
    <nct_id>NCT01651013</nct_id>
  </id_info>
  <brief_title>Observational Study on Treatment of Metastatic Colorectal Cancer and the Role of K-Ras</brief_title>
  <acronym>CALLAS</acronym>
  <official_title>Multicentered Observational Prospective Cohort Study on the Treatment of Metastatic Colorectal Cancer and the Role of Evaluating K-Ras</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to describe the treatments received and outcomes of patients
      with metastatic colorectal cancer,  what percentage of these patients have K-Ras mutation of
      the tumor, and to describe the costs of treatments. Information will also be collected
      regarding risk factors, variables among treatment centers and patients, and explorative
      analyses will be done to try to identify factors that impact prognosis and factors that
      predict tolerability and response to treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>percentage of patients enrolled in a clinical trial</measure>
    <time_frame>two years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>percentage of patients who undergo K-Ras mutation study</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients with K-Ras mutation</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <other_outcome>
    <measure>metastatic colorectal cancer treatments used in clinical practice, according to participating center</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>patient outcome according to K-Ras status</measure>
    <time_frame>two years</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>estimated costs per treatment per center</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>disease outcome per patient per treatment received</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>factors that influence patient prognosis</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>exploratory analyses</description>
  </other_outcome>
  <other_outcome>
    <measure>predictive factors for response to treatment</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>exploratory analyses</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>metastatic colorectal cancer</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients at participating Institutes who are candidate for first-line treatment of
        metastatic colorectal cancer
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic diagnosis colorectal carcinoma

          -  Metastatic disease

          -  Signed informed consent

        Exclusion Criteria:

          -  Prior treatment of metastatic colorectal cancer

          -  Refusal or incapability of providing informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R. V. Iaffaioli, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>G. Nasti, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>M. C. Piccirillo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Naples</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francesco Perrone, M.D., Ph.D.</last_name>
    <phone>+39 081 5903571</phone>
    <email>francesco.perrone@usc-intnapoli.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marilina Piccirillo, M.D.</last_name>
    <phone>+39 081 5903383</phone>
    <email>marilina.piccirillo@usc-intnapoli.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>A.O.G. Rummo</name>
      <address>
        <city>Benevento</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori , Oncologia Medica - Dipartimento Entero-proctologico</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Umberto I</name>
      <address>
        <city>Nocera Inferiore</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>C:R.O. Regione Basilicata Ospedale Giustino Fortunato</name>
      <address>
        <city>Rionero in Vulture</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 3, 2014</lastchanged_date>
  <firstreceived_date>July 24, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
